Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
This Month’s Highlights
You have accessRestricted Access

This Month’s Highlights

JASN November 2013, 24 (11) i; DOI: https://doi.org/10.1681/ASN.2013070789
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

BASIC RESEARCH

Inhibiting CDA1 Reduces Diabetic Nephropathy

Pathological activation of TGF-β signaling contributes to renal fibrogenesis in diabetic nephropathy, but direct inhibition of TGF-β or its receptors has adverse consequences. In this issue, Chai et al. report that genetic deletion of the gene encoding CDA1 attenuates, but does not completely block, TGF-β signaling and reduces diabetes-associated renal injury in mice. In contrast to TGF-β-deficient mice, CDA1-deficient mice were viable and healthy. Moreover, the authors identified elevated expression of CDA1 in sclerotic glomeruli of diabetic and non-diabetic patients. Overall, these results indicate that CDA1 warrants investigation as a target for reducing TGF-β-induced renal damage. See Chai et al., pages 1782–1792.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Soluble CR1 Restores Physiological Complement Activity

In dense deposit disease and C3GN, dysregulation of the alternative pathway of complement leads to glomerular accumulation of complement proteins and progressive kidney decline. Zhang et al. assessed the capacity of CR1, a cell surface glycoprotein that modulates the complement cascade, to restore complement regulation in these diseases. Soluble CR1 arrested complement activation in vitro, reduced glomerular deposition of complement fragments in mouse models, and normalized complement activity in a pediatric patient with dense deposit disease. Taken together, these results support the further exploration of soluble CR1 as a treatment for glomerulopathies associated with chronic activation of the alternative pathway of complement. See Zhang et al., pages 1820–1829.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

LMX1B Regulates the Actin Cytoskeleton in Podocytes

Nail-patella syndrome, characterized by abnormal development of the kidneys and other organs, is caused by mutations in LMX1B. Studies in knockout mouse models implicated LMX1B in podocyte development, but the mechanisms involved remain controversial. Burghardt et al. developed an inducible podocyte-specific Lmx1b knockout mouse and report that LMX1B is required for both the acquisition and maintenance of podocyte differentiation. Additional studies performed in vitro and in zebrafish indicate that LMX1B controls these processes through regulation of the actin cytoskeleton, providing crucial insight into the mechanisms underlying renal complications in this ultra-rare disease. See Burghardt et al., pages 1830–1848.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Complement-Activating Microparticles Cause Renal Injury

Dysregulation of the alternative pathway of complement contributes to renal diseases, including atypical hemolytic uremic syndrome, and is exacerbated by treatment with calcineurin inhibitors. Renner et al. investigated the complement-activating potential of microparticles released by injured endothelial cells. In mice, cyclosporine treatment triggered microparticle release from endothelial cells, glomerular activation of the alternative pathway of complement, and vascular and renal damage. In renal transplant patients, the number of circulating microparticles increased after the start of tacrolimus. Together with in vitro study results, these data point to endothelial injury throughout the body as a cause of renal damage. See Renner et al., pages 1849–1862.

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

CLINICAL EPIDEMIOLOGY

Clinical Validation of Urinary Biomarkers of Incident CKD

Novel biomarkers capable of detecting subclinical kidney injury and identifying affected renal pathways remain elusive. Here, O’Seaghdha et al. report the results of a study examining the association of 14 urinary biomarkers with incident CKD and a broad range of adverse outcomes in a community-based setting. Individual markers within this panel associated with several adverse clinical outcomes, including outcomes not identified by existing clinical markers. While validation of these results in more diverse populations is necessary, clinical measurement of these biomarkers may predict CKD and other adverse outcomes, permitting therapeutic intervention. See O’Seaghdha et al., pages 1880–1888.

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

CLINICAL MEDICINE

Urine Metabolites Link Mitochondrial Metabolism and Diabetic Kidney Disease

Urine metabolomics offers the potential to identify molecular pathways involved in renal diseases. Sharma et al. used gas chromatography to quantify urine metabolites in patients with diabetes and found reduced levels of urinary organic acids, most of which are linked to mitochondrial metabolism. Consistent with this, kidney sections from patients with diabetes expressed less mitochondrial protein, and urine exosomes from patients with diabetes and CKD contained less mitochondrial DNA. These results support the prognostic value of urine metabolites in diabetic kidney disease and provide insight into the relationship between mitochondrial function and kidney disease. See Sharma et al., pages 1901–1912.

Figure6
  • Download figure
  • Open in new tab
  • Download powerpoint
  • Copyright © 2013 by the American Society of Nephrology
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 24 (11)
Journal of the American Society of Nephrology
Vol. 24, Issue 11
November 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
This Month’s Highlights
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
This Month’s Highlights
JASN Nov 2013, 24 (11) i; DOI: 10.1681/ASN.2013070789

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
This Month’s Highlights
JASN Nov 2013, 24 (11) i; DOI: 10.1681/ASN.2013070789
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • BASIC RESEARCH
    • CLINICAL EPIDEMIOLOGY
    • CLINICAL MEDICINE
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • This Month's Highlights
  • This Month’s Highlights
  • This Month's Highlights
Show more This Month’s Highlights

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire